Acute Coronary Syndrome (ACS) represents a spectrum of conditions, which are associated with acute myocardial ischemia. Over the past decades, significant advancements have been made in the management of ACS, resulting in improved patient outcomes. This article aims to provide a comprehensive overview of these advancements.
Improved risk stratification tools have played a pivotal role in ACS management. The GRACE and TIMI risk scores, for instance, have enabled clinicians to better predict patient outcomes, guiding treatment decisions. The use of high-sensitivity cardiac troponins has also improved the early diagnosis of ACS.
Pharmacological management of ACS has seen remarkable advancements. The introduction of novel antiplatelet agents, such as ticagrelor and prasugrel, has significantly reduced the risk of recurrent ischemic events. Moreover, the emergence of non-vitamin K oral anticoagulants has provided an alternative to traditional anticoagulants, with a comparable efficacy and better safety profile.
Interventional cardiology has revolutionized the management of ACS. Percutaneous coronary intervention (PCI) has become the standard of care for ST-segment elevation myocardial infarction (STEMI). Furthermore, the development of drug-eluting stents has reduced the risk of restenosis. Recent studies also suggest a potential role for complete revascularization in selected patients.
The importance of secondary prevention following an ACS event is now well-recognized. Comprehensive cardiac rehabilitation programs, lifestyle modifications, and adherence to guideline-directed medical therapy have all been shown to improve long-term outcomes.
The landscape of ACS management has significantly evolved over the past decades. These advancements have led to a paradigm shift in ACS management, with an emphasis on early diagnosis, risk stratification, aggressive intervention, and comprehensive post-ACS care. As healthcare professionals, it is imperative to stay updated with these advancements to provide optimal care to our patients.
1.
Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer
2.
Black Canadians Face Multiple Barriers to Blood Donation
3.
Stop Calling It Cancer; The Alcohol Paradox; Rural Patients Lose Ground in Screening
4.
Experts say oncology, primary care coordination necessary for best cancer patient outcomes
5.
Neural networks and label-free microscopy enable accurate detection of pancreatic tumors
1.
Machine Learning in Hematology: Boosting Diagnostic Precision and Speed in Medical Practice
2.
Advancing Cancer Care: Insights into Oncology Trials, Immunotherapy, and CAR-T Innovations
3.
Clinical Frameworks in Hematology for Better Care
4.
Empowering Lung Cancer Diagnosis Through the Synergy of Advanced Technologies and Artificial Intelligence
5.
The Benefits of Understanding Haptoglobin High: What You Need to Know
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
3.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation